文献速递泌尿生殖MR

多参数前列腺MRI中外周带中等风险病变:基于局灶性对比增强的PI-RADSv2风险分层算法的频率与验证

Peripheral zone lesions of intermediary risk in multiparametric prostate MRI: Frequency and validation of the PI-RADSv2 risk stratification algorithm based on focal contrast enhancement.
PubMed 文献 · Eur J Radiol · 2017-12-14

回顾性分析172例患者315个病理验证病灶,外周带PI-RADS 3、升级PI-RADS 4和基于ADC值显著降低的PI-RADS 4频率分别为10.8%、10.8%和20.3%,癌症率分别为8.8%(3/34)、23.5%(8/34)和40.6%(26/64),P<0.01。观察者间评估对比增强的一致性为中等(kappa 0.46-0.5)。

要点

  • 外周带PI-RADS 3、升级PI-RADS 4和基于ADC值显著降低的PI-RADS 4癌症率呈递增趋势(8.8%、23.5%、40.6%,P<0.01)。
  • 外周带中等风险病变(DWI序列)占所有前列腺病变的21.6%。
  • 对比增强评估的观察者间一致性为中等(kappa 0.46-0.5)。

核心结论

  • 从PI-RADSv2类别3到升级类别4再到基于ADC值显著降低的类别4,癌症率呈递增趋势;未来PI-RADS版本中升级类别4和基于ADC值显著降低的类别4的癌症率应处于相似范围,建议未来研究分别报告以生成荟萃分析数据库。

研究设计与样本

  • 回顾性分析172例连续接受前列腺MRI患者的315个组织病理学验证病灶,比较外周带类别3或类别4病变的癌症率(双侧卡方检验),并由两名盲法放射科医师基于扩散加权序列评估类别3病变的对比增强以确定观察者间一致性。

诊断标准与关键数值

  • 外周带PI-RADS 3、升级PI-RADS 4和基于ADC值显著降低的PI-RADS 4的频率分别为10.8%、10.8%和20.3%;癌症率(仅显著癌)分别为8.8%(3/34)、23.5%(8/34)和40.6%(26/64),P<0.01;对比增强评估的观察者间一致性kappa值为0.46至0.5。

临床应用与阅片要点

  • 作者认为未来PI-RADS版本中患者管理建议可能与评估类别挂钩,升级类别4和基于ADC值显著降低的类别4的癌症率应处于相似范围;作者建议未来研究应分别报告升级类别4和基于ADC值显著降低的类别4以生成荟萃分析数据库。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To validate the risk stratification algorithm of the Prostate Imaging Reporting and Data System (PI-RADSv2) for intermediary risk lesions (PI-RADSv2 category 3) in the peripheral zone based on focal contrast enhancement and to compare cancer rates in category 3, upgraded category 4 and category 4 based on markedly low ADC value.

MATERIALS AND METHODS: We retrospectively analyze 172 consecutive patients undergoing prostate MRI with 315 histopathologically verified lesions. We select all lesions either assigned category 3 or category 4 in the peripheral zone for further analysis. We compare cancer rates with the two-sided chi-squared test. To determine inter-observer agreement about contrast enhancement two blinded radiologists evaluate the subset of category 3 lesions based on the diffusion weighted sequence.

RESULTS: The frequency of peripheral PI-RADS 3, upgraded PI-RADS 4 and PI-RADS 4 lesions based on markedly low ADC value is 10.8%, 10.8% and 20.3%, respectively. Cancer rates (significant cancer only) in these subgroups are 8.8% (3/34), 23.5% (8/34) and 40.6% (26/64), P < 0.01. Inter-observer agreement is moderate for evaluation of contrast enhancement with kappa values between 0.46 and 0.5.

CONCLUSION: We demonstrate a trend of increasing cancer rate from PI-RADSv2 category 3 to upgraded category 4 to category 4 based on markedly low ADC value. Peripheral lesions of intermediary risk in the diffusion weighted sequence account for 21.6% of all prostate lesions encountered. Since it is likely that patient management recommendations will be linked to assessment categories in future versions of PI-RADS, cancer rates in upgraded category 4 and category 4 based on markedly low ADC values should be in a similar range. We conclude that in future studies of PI-RADSv2 upgraded category 4 and category 4 based on markedly low ADC value should be reported separately to generate a database for meta-analysis of cancer rates.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Benndorf M, Waibel L, Krönig M, et al. Peripheral zone lesions of intermediary risk in multiparametric prostate MRI: Frequency and validation of the PI-RADSv2 risk stratification algorithm based on focal contrast enhancement. Eur J Radiol. 2017. PMID: 29362152. doi:10.1016/j.ejrad.2017.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。